Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 4/2016

06.10.2016 | Neurogenic Bladder (C Powell, Section Editor)

Cystectomy for Neurogenic Bladder

verfasst von: Elizabeth Timbrook Brown, Joshua A. Cohn, Melissa R. Kaufman, Douglas Milam, Roger R. Dmochowski, W. Stuart Reynolds

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Patients with a myriad of neurologic conditions can develop urinary symptoms as a result of impaired bladder function. Conservative management options for neurogenic bladder (NGB) may include catheterization and medical therapy. However, refractory individuals may require more aggressive intervention such as onabotulinumtoxinA injections or bladder augmentation. As a last resort, urinary diversion may be indicated for end-stage lower urinary tract dysfunction secondary to NGB. Urinary diversion may be performed with or without cystectomy. However, leaving the defunctionalized bladder in situ may lead to pyocystis, secondary carcinoma, or pain. As a result, there has been an increasing trend to perform a concomitant cystectomy at the time of urinary diversion. While this eliminates the sequelae of the retained bladder, performing a cystectomy at the time of urinary diversion can also increase the morbidity of the procedure.
Literatur
1.
Brown ET, Krlin R, Winters JC. Urodynamics: examining the current role of UDS testing. What is the role of urodynamic testing in light of recent AUA Urodynamics and Overactive Bladder Guidelines and the VALUE study? Lower Urinary Tract Symptoms and Voiding Dysfunction. Curr Urol Rep. 2013;14(5):403–8.CrossRefPubMed
2.••
Winters JC, Dmochowski RR, Goldman HB, et al. Urodynamic studies in adults: AUA/SUFU guideline. J Urol. 2012;188:2464–72. Summary of the AUA Guidelines on Urodynamics.
3.
Ginsberg D. Indications and complications of cystectomy in patients with neurogenic bladder. J Urol. 2010;184:10–1.CrossRefPubMed
4.
Kurpad R, Kennelly M. The evaluation and management of refractory neurogenic overactive bladder. Curr Urol Rep. 2014;15:444.CrossRefPubMed
5.
Goessaert A, Everaert K. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. Expert Rev Neurother. 2012;12(7):763–75.CrossRefPubMed
6.
Lisenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med. 2013;36(5):402–19.CrossRef
7.
Sajadi KP, Goldman HB. Bladder augmentation and urinary diversion for neurogenic LUTS: current indications. Curr Urol Rep. 2012;13:389–93.CrossRefPubMed
8.
Gamé X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of urinary tract infections. Eur Urol. 2008;53(3):613–8.CrossRefPubMed
9.
Gurung, Attar KH, Abdul-Rahman A, et al. Long-term outcomes of augmentation ileocystoplasty in patients with spinal cord injury: a minimum of 10 years of follow-up. BJU Int. 2012;109:1236–42.CrossRefPubMed
10.•
Rowley M, Clemens J, Latini J, et al. Simple cystectomy: outcomes of a new operative technique. Urology. 2011;78:942–5. Describes the supratrigonal technique for cystectomy that we currently employ.CrossRefPubMed
11.
Singh G, Wilkinson JM, Thomas DG. Supravesical diversion for incontinence: a long-term follow-up. Br J Urol. 1998;79:348–53.CrossRef
12.
Chartier-Kastler EJ, Mozer P, Denys P, et al. Neurogenic bladder management and cutaneous non-continent ileal conduit. Spinal Cord. 2002;40:443–8.CrossRefPubMed
13.
Eigner EB, Freiha FS. The fate of the remaining bladder following supravesical diversion. J Urol. 1990;144:31.PubMed
14.
Lawrence A, Hu B, Lee O, et al. Pyocystis after urinary diversion for incontinence—is a concomitant cystectomy necessary? Urology. 2013;82(5):1161–5.CrossRefPubMed
15.
Cheng JN, Lawrentschuk N, Gyomber D, et al. Cystectomy in patients with spinal cord injury: indications and long-term outcomes. J Urol. 2010;184(1):92–8.CrossRefPubMed
16.
Groah SL, Weitzenkamp DA, Lemmertse DP, et al. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil. 2002;83:346.CrossRefPubMed
17.
Cohn J, Large M, Richards K, et al. Cystectomy and urinary diversion as management of treatment-refractory benign disease: the impact of preoperative urological conditions on perioperative outcomes. Int J Urol. 2014;21:382–6.CrossRefPubMed
18.
Chong J, Dolat MT, Klausner A, et al. The role of cystectomy for non-malignant bladder conditions: a review. Can J Urol. 2014;21(5):7433–41.PubMed
19.
Neulander E, Rivera I, Eisenbrown N, et al. Simple cystectomy in patients requiring urinary diversion. J Urol. 2000;164:1169–72.CrossRefPubMed
20.
Gobeaux N, Yates D, Denys P, et al. Supratrigonal cystectomy with Hautmann pouch as treatment for neurogenic bladder in spinal cord injury patients: long-term functional results. Neurourol Urodyn. 2012;31:672–6.CrossRefPubMed
21.
Osborn D, Dmochowski R, Kaufman M, et al. Cystectomy with urinary diversion for benign disease: indications and outcomes. Urology. 2014;84:1433–7.CrossRef
22.
Legrand G, Rouprêt M, Comperat E, et al. Functional outcomes after management of end-stage neurological bladder dysfunction with ileal conduit in a multiple sclerosis population: a monocentric experience. Urology. 2011;78(4):937–41.CrossRefPubMed
23.
Guillotreau J, Castel-Lacanal, Roumiguié M, et al. Prospective study of the impact on quality of life of cystectomy with ileal conduit urinary diversion for neurogenic bladder dysfunction. Neurourol Urodyn. 2011;30:1503–6.CrossRefPubMed
24.
Moore D, Cohn J, Brown ET, et. al. Post-operative complications after laparotomy in adult patients with spina bifida. Presented at the 2016 Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction conference in New Orleans, LA.
25.•
Brown ET, Osborn D, Mock S, et. al. Perioperative complications of conduit urinary diversion with concomitant cystectomy for benign indications: a population-based analysis. Neurourol Urodyn. 2016. doi:10.​1002/​nau.​23135. National analysis of complications of cystectomy for bengin indications.
26.•
Brown ET, Osborn D, Mock S, et. al. Temporal trends in conduit urinary diversion with concomitant cystectomy for benign indications: a population-based analysis. Urology. 2016. doi:10.​1016/​j.​urology.​2016.​06.​035. National analysis of outcomes for cystectomy for benign indications.
27.
Cody JD, Nabi G, Dublin N, et al. Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev 2012;2.
28.
Stohrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56:81–8.CrossRefPubMed
29.
Klausner AP, Steers WD. The neurogenic bladder: an update with management strategies for primary care physicians. Med Clin N Am. 2011;95(1):111–20.CrossRefPubMed
30.
Chen G, Liao L. Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease. Spinal Cord. 2014.
31.
Lombardi G, Musco S, Celso M, Del Corso F, Del Popolo G. Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience. Spinal Cord. 2014;52(3):241–5.CrossRefPubMed
32.
Wöllner J, Krebs J, Pannek J. Sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction. Spinal Cord. 2016;54(2):137–40.CrossRefPubMed
Metadaten
Titel
Cystectomy for Neurogenic Bladder
verfasst von
Elizabeth Timbrook Brown
Joshua A. Cohn
Melissa R. Kaufman
Douglas Milam
Roger R. Dmochowski
W. Stuart Reynolds
Publikationsdatum
06.10.2016
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 4/2016
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-016-0389-9

Weitere Artikel der Ausgabe 4/2016

Current Bladder Dysfunction Reports 4/2016 Zur Ausgabe

Neurogenic Bladder (C Powell, Section Editor)

Urethral Stricture in the Spinal Cord Injured Patient—What Are the Unique Considerations?

Neurogenic Bladder (C Powell, Section Editor)

Conditional Electrical Stimulation in Animal and Human Models for Neurogenic Bladder: Working Toward a Neuroprosthesis

Neurogenic Bladder (C Powell, Section Editor)

Does the Technique or Pattern Matter When Injecting OnabotulinumtoxinA?

Neurogenic Bladder (C Powell, Section Editor)

Worldwide Utilization Patterns of Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Minimally Invasive Approaches to Continent Urinary Diversion

Neurogenic Bladder (C Powell, Section Editor)

Using the Native Afferent Nervous System to Sense Bladder Fullness: State of the Art

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise